Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade war continues to escalate with new tariffs. While PFE is an American company with manufacturing facilities in the U.S., it also has supply chains that span the globe as it does business in Europe and other regions.
Companies with large global presences, like Pfizer, stand to lose a lot in the ongoing trade war. That’s due to the potential tariffs it faces, both on importing goods into the U.S. and into other countries, as many have retaliated against Trump’s trade policies with tariffs of their own.
The trade war has investors spooked, with the stock market trading out of fear. That’s resulted in an 18.85% drop in PFE stock since the start of the year. This negative movement continued today, with the shares dropping another 3%.
Analyst Opinions on PFE Stock
Several analysts have weighed in on Pfizer stock recently, evaluating the shares as the trade war continues. For example, Goldman Sachs analyst Asad Haider downgraded the stock to Hold and lowered its price target from $32 to $25. The analyst highlighted vaccine revenue concerns as one of the biggest reasons for this neutral stance.
4.5-star UBS analyst Trung Huynh also recently weighed in on PFE stock. He maintained a Hold rating and cut his price target for the shares from $28 to $24, representing a potential 13.05% upside.
Finally, Jefferies analyst Akash Tewari reiterated a Buy rating and $34 price target for PFE stock, representing a possible 60.15% increase.
Is PFE Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Pfizer is Moderate Buy, based on five Buy and 10 Hold ratings over the last three months. With that comes an average price target of $29.54, representing a potential 39.14% upside for PFE stock.
